Novel antithrombotic approaches to coronary artery disease
References (24)
- et al.
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of restenosis results at six months
Lancet
(1994) - et al.
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
J Am Coll Cardiol
(1993) - et al.
Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator
J Biol Chem
(1989) Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
Br Med J
(1994)- et al.
- et al.
Clinical trials of platelet receptor inhibitors
Thromb Haemost
(1993) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
N Engl J Med
(1994)- et al.
Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study
Circulation
(1993) - et al.
Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
Circulation
(1994) - Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL,...
Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trials
J Am Coll Cardiol
(1994)
HIT (Hirudin for the Improvement of Thrombolysis): results of a dose escalation study
Circulation
(1993)
Cited by (51)
Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels
2019, Molecular TherapyCitation Excerpt :The three gpIIb/IIIa inhibitors available clinically to treat acute thrombosis are Abciximab, Eptifibatide, and Tirofiban. These agents significantly improved outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCIs).11 When tested in acute ischemic stroke, however, they resulted in a significant increase in intracranial hemorrhage without improvement in morbidity or mortality.12
Onset of force development as a marker of thrombin generation in whole blood: The thrombin generation time (TGT)
2003, Journal of Thrombosis and HaemostasisThe progression of thrombus in an ex-vivo shunt model evaluated by intravascular ultrasound radiofrequency analysis
1999, Ultrasound in Medicine and BiologyIn-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial (GRAMI trial)
1998, American Journal of CardiologyInhibition of platelet-mediated clot retraction by integrin antagonists
1998, Thrombosis ResearchOral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates
1998, Thrombosis Research
Copyright © 1995 Published by Elsevier Inc.